Drug Trial Radar · NCT05163041
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Nov 2, 2021
Primary completion
Aug 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- BicycleTx LimitedIndustry
- Sponsor type
- Industry
- First posted
- Dec 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study is evaluating a drug called BT7480 alone and in combination with nivolumab in participants with advanced solid tumors associated with Nectin-4 expression. The main goals of the study are to: * Find the recommended dose of BT7480 that can be given safely to participants alone and in combination with nivolumab * Learn about the side effects and effectiveness of BT7480 alone and in combination with nivolumab * Learn about the effect BT7480 has on the body and how BT7480 is cleared by the body * Learn about the side effects and effectiveness of BT7480 in patients with reduced kidney function
Conditions
- Advanced Solid Tumor
Interventions
BT7480Drug
Participants will receive a 60 minute IV infusion of BT7480 once weekly (i.e., on Days 1,8,15 and 22) during a 28-day cycle
NivolumabDrug
Nivolumab will be given as a 240mg dose every 2 weeks administered as per local labelling as a 30 minute IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with treatment emergent adverse events in dose escalation phaseTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until 30 (+/-5) days after the last dose of study drug
- Number of patients with treatment emergent adverse events in dose escalation phaseTime frame: From Cycle 1 Day 1 (each cycle is 28 days) until 125 (+/-5) days after the last dose of study drug
- Confirmed response rate as measured by overall response rate (ORR) to demonstrate clinical activity following treatment with BT7480 in dose expansion phaseTime frame: From Cycle 1 Day 1 (each cycle is 28 days) through study completion, an average of 6 months
- Confirmed response rate as measured by clinical benefit rate (CBR) to demonstrate clinical activity following treatment with BT7480 in dose expansion phaseTime frame: From Cycle 1 Day 1 (each cycle is 28 days) through study completion, an average of 6 months
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
State University of Iowa
Iowa City, Iowa
Columbia University Irving Medical Center
New York, New York
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Fox Chase Cancer Center
Philadelphia, Pennsylvania
MD Anderson Cancer Center
Houston, Texas
START Center for Cancer Care
San Antonio, Texas
Virginia Cancer Specialists
Fairfax, Virginia
The Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.